• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medicare approves coverage for Second Sight’s Argus II ‘bionic eye’

Medicare approves coverage for Second Sight’s Argus II ‘bionic eye’

August 15, 2013 By Arezu Sarvestani

YYYYALTTAG

Second Sight Medical touted Medicare coverage for its Argus II "bionic eye" implant, a retinal prosthesis designed to help restore some vision to patients blinded by a rare disease.

The 1st-of-its-kind technology is comprised of 2 main components: an eyeglass-mounted camera and an electrical stimulator implanted in the eye. The device converts images captured by the camera into a series of electrical pulses that are transmitted wirelessly to electrodes in the retina to simulate vision.

FDA regulators in February approved Argus II for treating blindness due to late stage retinitis pigmentosa, a condition that leaves patients with either bare light perception or none at all. There is currently no cure for the rare condition, which is diagnosed about 250 times each year.

"This is a game changer in sight-affecting diseases, that represents a huge step forward for the field and for these patients who were without any available treatment options until now," Second Sight president & CEO Dr. Robert Greenberg said at the time.

Second Sight in June launched 12 U.S. centers to begin consultations for the Argus II, and the company in July launched a $10.5 million equity funding round.

Medicare granted the Argus II device reimbursement for both inpatient (new technology add-on payments) and outpatient settings (transitional pass through payment), the company announced. CMS is slated in October to release more information on billing, coding and payment for outpatient reimbursement. Inpatient coverage is available through the Medicare Inpatient Prospective Payment System will be identified by a new ICD-9-CM procedure code 14.81, Second Sight said.

Filed Under: Medicare, News Well, Optical/Ophthalmic Tagged With: Centers for Medicare and Medicaid Services (CMS), Insurance, second-sight-medical

More recent news

  • AdvaMed calls for medtech tariff exemptions at Senate hearing
  • GE HealthCare, Raydiant Oximetry partner on fetal oxygen saturation tech
  • Terumo Neuro launches new stroke catheter in the U.S.
  • EnVVeno has first-in-human heart valve data, expects FDA decision this year
  • Axoft makes Fleuron BCI material available for purchase, inks license deal with Stanford

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy